SciBase Holding AB (publ) (SCIB.ST)
SEK 0.39
(2.36%)
SEK 0.39
(2.36%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -55.58 Million SEK | -39.31% |
| 2022 | -39.89 Million SEK | 4.3% |
| 2021 | -41.69 Million SEK | -19.15% |
| 2020 | -34.98 Million SEK | 11.51% |
| 2019 | -39.53 Million SEK | 10.58% |
| 2018 | -44.21 Million SEK | -4.12% |
| 2017 | -42.46 Million SEK | 20.01% |
| 2016 | -53.08 Million SEK | -27.82% |
| 2015 | -41.53 Million SEK | -7.17% |
| 2014 | -38.75 Million SEK | 51.25% |
| 2013 | -79.5 Million SEK | -94.08% |
| 2012 | -40.96 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -15.05 Million SEK | -38.57% |
| 2024 Q1 | -10.86 Million SEK | 47.13% |
| 2023 Q2 | -11.35 Million SEK | -4.1% |
| 2023 FY | -55.58 Million SEK | -39.31% |
| 2023 Q4 | -20.54 Million SEK | -60.65% |
| 2023 Q3 | -12.78 Million SEK | -12.63% |
| 2023 Q1 | -10.9 Million SEK | 81.15% |
| 2022 Q1 | -9.73 Million SEK | 29.71% |
| 2022 Q4 | -57.85 Million SEK | -862.45% |
| 2022 FY | -39.89 Million SEK | 4.3% |
| 2022 Q2 | -6.72 Million SEK | 30.94% |
| 2022 Q3 | -6.01 Million SEK | 10.6% |
| 2021 Q1 | -8.15 Million SEK | 17.14% |
| 2021 FY | -41.69 Million SEK | -19.15% |
| 2021 Q4 | -13.85 Million SEK | -60.66% |
| 2021 Q3 | -8.62 Million SEK | 22.68% |
| 2021 Q2 | -11.15 Million SEK | -36.77% |
| 2020 Q1 | -8.93 Million SEK | 12.45% |
| 2020 FY | -34.98 Million SEK | 11.51% |
| 2020 Q4 | -9.83 Million SEK | -33.86% |
| 2020 Q3 | -7.35 Million SEK | 17.08% |
| 2020 Q2 | -8.86 Million SEK | 0.81% |
| 2019 FY | -39.53 Million SEK | 10.58% |
| 2019 Q4 | -10.2 Million SEK | -3.44% |
| 2019 Q3 | -9.86 Million SEK | 7.02% |
| 2019 Q2 | -10.61 Million SEK | -19.17% |
| 2019 Q1 | -8.9 Million SEK | 22.6% |
| 2018 Q2 | -10.29 Million SEK | -6.65% |
| 2018 Q4 | -11.5 Million SEK | 9.79% |
| 2018 Q1 | -9.65 Million SEK | 6.22% |
| 2018 FY | -44.21 Million SEK | -4.12% |
| 2018 Q3 | -12.75 Million SEK | -23.85% |
| 2017 FY | -42.46 Million SEK | 20.01% |
| 2017 Q2 | -11.74 Million SEK | -1.15% |
| 2017 Q4 | -10.29 Million SEK | -16.87% |
| 2017 Q1 | -11.61 Million SEK | 20.59% |
| 2017 Q3 | -8.81 Million SEK | 25.0% |
| 2016 Q1 | -11.6 Million SEK | -4.0% |
| 2016 Q3 | -12.39 Million SEK | 14.33% |
| 2016 Q2 | -14.46 Million SEK | -24.72% |
| 2016 Q4 | -14.62 Million SEK | -17.97% |
| 2016 FY | -53.08 Million SEK | -27.82% |
| 2015 Q3 | -10.26 Million SEK | 6.21% |
| 2015 Q2 | -10.93 Million SEK | -19.17% |
| 2015 Q1 | -9.17 Million SEK | 10.5% |
| 2015 FY | -41.53 Million SEK | -7.17% |
| 2015 Q4 | -11.15 Million SEK | -8.71% |
| 2014 Q3 | -7.93 Million SEK | 31.31% |
| 2014 Q4 | -10.25 Million SEK | -29.25% |
| 2014 Q2 | -11.55 Million SEK | -28.18% |
| 2014 Q1 | -9.01 Million SEK | 0.0% |
| 2014 FY | -38.75 Million SEK | 51.25% |
| 2013 FY | -79.5 Million SEK | -94.08% |
| 2012 FY | -40.96 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Acarix AB (publ) | -77.83 Million SEK | 28.59% |
| ADDvise Group AB (publ) | 103.5 Million SEK | 153.705% |
| ADDvise Group AB (publ) | 103.5 Million SEK | 153.705% |
| Arcoma AB | 2.56 Million SEK | 2267.902% |
| Bactiguard Holding AB (publ) | -138.38 Million SEK | 59.832% |
| BICO Group AB (publ) | -835.7 Million SEK | 93.349% |
| Boule Diagnostics AB (publ) | 24.97 Million SEK | 322.545% |
| CellaVision AB (publ) | 130.3 Million SEK | 142.656% |
| Clinical Laserthermia Systems AB (publ) | -79.79 Million SEK | 30.338% |
| Chordate Medical Holding AB (publ) | -29.18 Million SEK | -90.446% |
| C-Rad AB (publ) | 35.52 Million SEK | 256.45% |
| Duearity AB (publ) | -26.19 Million SEK | -112.237% |
| Dignitana AB (publ) | -17.36 Million SEK | -220.135% |
| Episurf Medical AB (publ) | -94.8 Million SEK | 41.366% |
| Getinge AB (publ) | 2.41 Billion SEK | 102.305% |
| Scandinavian Real Heart AB (Publ) | -67.97 Million SEK | 18.23% |
| Iconovo AB (publ) | -45.89 Million SEK | -21.116% |
| Integrum AB (publ) | 4.03 Million SEK | 1478.433% |
| Luxbright AB (publ) | -25.37 Million SEK | -119.053% |
| Mentice AB (publ) | -2.81 Million SEK | -1873.198% |
| OssDsign AB (publ) | -130.49 Million SEK | 57.404% |
| Paxman AB (publ) | 8.33 Million SEK | 767.287% |
| Promimic AB (publ) | -9.22 Million SEK | -502.743% |
| Qlife Holding AB (publ) | -159.95 Million SEK | 65.25% |
| ScandiDos AB (publ) | -14.64 Million SEK | -279.498% |
| Sectra AB (publ) | 428.38 Million SEK | 112.975% |
| Sedana Medical AB (publ) | -59.61 Million SEK | 6.755% |
| Senzime AB (publ) | -134.14 Million SEK | 58.565% |
| SpectraCure AB (publ) | -20.44 Million SEK | -171.929% |
| Stille AB | 26.64 Million SEK | 308.605% |
| Vitrolife AB (publ) | -3.85 Billion SEK | 98.557% |
| Xvivo Perfusion AB (publ) | 91.82 Million SEK | 160.537% |